carismatx.com (CARM) - מקדם חוב לטווח ארוך להון

Carisma Therapeutics (CARM) possesses significant market influence due to the inelastic demand for CAR-macrophages. The long-term debt-to-equity structure confirms financial stability, where 0.00 captures the magnitude of this parameter. Innovative methods for combating solid breast and lung tumors create a unique advantage. Meanwhile, the business ignores macroeconomic fluctuations, relying instead on clinical trial results.

Developing ethical cancer immunotherapy in compliance with ESG standards requires significant capital expenditures in biolaboratories. The ratio of long-term loans to equity measures the dependence of Carisma Therapeutics (CARM) on external financing with maturities exceeding one year. The current value of 0.00 demonstrates the level of debt load relative to shareholder value. The trend of this indicator reflects the balance between credit risk and investment activity. Investors view this metric as an indicator of the business's financial stability.